Zacks Investment Research downgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a hold rating to a sell rating in a research report report published on Wednesday morning.
According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “
A number of other equities analysts have also recently commented on DCPH. BidaskClub raised Deciphera Pharmaceuticals from a buy rating to a strong-buy rating in a report on Saturday, February 10th. B. Riley began coverage on Deciphera Pharmaceuticals in a report on Friday, February 16th. They set a buy rating and a $43.00 target price for the company. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Deciphera Pharmaceuticals currently has a consensus rating of Buy and a consensus price target of $41.14.
Shares of Deciphera Pharmaceuticals stock opened at $24.00 on Wednesday. Deciphera Pharmaceuticals has a 12 month low of $15.15 and a 12 month high of $29.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.35 and a quick ratio of 14.35.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Wednesday, March 28th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.19). equities research analysts expect that Deciphera Pharmaceuticals will post -2.36 EPS for the current fiscal year.
Several large investors have recently bought and sold shares of the stock. Millennium Management LLC increased its holdings in shares of Deciphera Pharmaceuticals by 5.9% in the fourth quarter. Millennium Management LLC now owns 728,583 shares of the company’s stock valued at $16,517,000 after purchasing an additional 40,352 shares during the last quarter. TIAA CREF Investment Management LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at approximately $257,000. Teachers Advisors LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at approximately $332,000. California State Teachers Retirement System acquired a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at approximately $295,000. Finally, Deutsche Bank AG acquired a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at approximately $410,000. 48.20% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Deciphera Pharmaceuticals (DCPH) Stock Rating Lowered by Zacks Investment Research” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/08/deciphera-pharmaceuticals-dcph-stock-rating-lowered-by-zacks-investment-research.html.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors.
Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.